Literature DB >> 28508962

Proteinuria rebound in IgA nephropathy associated with obesity-related glomerulopathy.

Hiro Matsukura1, Masako Sakakibara2, Izumi Sakamoto2, Miho Tatematsu2.   

Abstract

IgA nephropathy (IgAN), the most prevalent primary chronic glomerulonephritis worldwide, has three major risk factors: hypertension, proteinuria >1 g/day, and severe renal lesions. Obesity also portends a poor prognosis. A Japanese boy with IgAN showed nephrotic syndrome at presentation. Pathological features resembled those of membranoproliferative glomerulonephritis (MPGN), although IgA deposition differed from MPGN and IgAN. Combination therapy improved renal lesions, but rebound deterioration of proteinuria occurred in this patient, who had marked obesity and hypertension. Serial kidney biopsy specimens were compatible with obesity-related glomerulopathy (ORG). Rebound proteinuria was apparently attributable to ORG rather than relapse and flaring up of IgAN.

Entities:  

Keywords:  IgA nephropathy; Membranoproliferative glomerulonephritis; Nephrotic syndrome; Obesity-related glomerulopathy; Proteinuria

Year:  2015        PMID: 28508962      PMCID: PMC5413749          DOI: 10.1007/s13730-015-0208-8

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  16 in total

1.  Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy.

Authors:  Francois Berthoux; Christophe Mariat; Nicolas Maillard
Journal:  Nephrol Dial Transplant       Date:  2013-09-11       Impact factor: 5.992

2.  Thin glomerular basement membrane nephropathy: incidence in 3471 consecutive renal biopsies examined by electron microscopy.

Authors:  Mark Haas
Journal:  Arch Pathol Lab Med       Date:  2006-05       Impact factor: 5.534

Review 3.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

4.  A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.

Authors:  N Yoshikawa; H Ito; T Sakai; Y Takekoshi; M Honda; M Awazu; K Ito; K Iitaka; Y Koitabashi; K Yamaoka; K Nakagawa; H Nakamura; S Matsuyama; Y Seino; N Takeda; S Hattori; M Ninomiya
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

Review 5.  The IgA nephropathy treatment dilemma.

Authors:  G B Appel; M Waldman
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

6.  Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kandai Nozu; Kazumoto Iijima; Yuko Shima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-12-10       Impact factor: 3.714

Review 7.  Nondiabetic consequences of obesity on kidney.

Authors:  Tarak Srivastava
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

8.  Renal injury in the extremely obese patients with normal renal function.

Authors:  A Serra; R Romero; D Lopez; M Navarro; A Esteve; N Perez; A Alastrue; A Ariza
Journal:  Kidney Int       Date:  2008-01-23       Impact factor: 10.612

9.  Prognostic indicators in childhood IgA nephropathy.

Authors:  N Yoshikawa; H Ito; H Nakamura
Journal:  Nephron       Date:  1992       Impact factor: 2.847

10.  IgA-associated glomerulonephritis with membranoproliferative glomerulonephritis-like pattern in two children.

Authors:  Kikuo Iitaka; Asako Yamamoto; Natsuko Ogawa; Toru Sekine; Shinya Tamai; Osamu Motoyama
Journal:  Clin Exp Nephrol       Date:  2003-12       Impact factor: 2.801

View more
  1 in total

1.  Overlapping obesity-related glomerulopathy and immunoglobulin A nephropathy: clinical and pathologic characteristics and prognosis.

Authors:  Junjun Zhang; Yongli Wang; Zhangsuo Liu; Bo Huang; Xutong Wang; Minhua Xie; Dan Yu; Ruxue Guo; Panfei Wang
Journal:  Clin Exp Nephrol       Date:  2021-04-02       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.